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Background: A randomized double-blind placebo controlled clinical study was
undertaken to investigate the safety and efficacy of a plant-based formulation
(DCBT1234-Lung KR), which earlier through 2 trials was found to improve FEV1 and
the quality of life of COPD patients.
Objective: The efficacy of DCBT1234-Lung KR was assessed using pulmonary
function tests, arterial blood gas (ABG) analyses and the clinical symptoms of COPD
in a 6-month study period against a matching placebo and a biomedical drug
combination (salbutamol+theophylline+bromhexine).
Methods: One hundred and five subjects aged between 35 and 85 years with a
smoking history of more than 20 pack years, showing little or no improvement in FEV1
upon a bronchial challenge of 200 mg of inhaled salbutamol and exhibiting ABG
percentage of less than 85% of oxygen saturation were taken up for the study. The
study had 3 arms viz., the plant-based formulation (DCBT1234-Lung KR), placebo and
salbutamol (12mg/day) plus theophylline (300mg/day) plus bromhexine (24mg/
day). The end point of the study was determined as an improvement of FEV1 by
200mL and/or increased ABG values (490% PaO2) and clinical symptoms like
dyspnoea, wheezing, cough, expectoration, disability, and sleep disturbances.
Results: DCBT1234-Lung KR patients showed statistically significant (95% level)
improvement in FEV1 and PaO2 in comparison with salbutamol+theophylline+brom-
hexine and placebo patients. Twenty-three per cent of DCBT1234-Lung KR patients,
19% of salbutamol+theophylline+bromhexine group and 12% of placebo group
patients showed the desired 200mL improvement in FEV1 values in comparison with
the other 2 arms. Improved PaO2 was observed in 15.4% of the DCBT1234-Lung KRElsevier Ltd. All rights reserved.
2607987; fax: +91 422 2607688.
gy@vsnl.com (P.M. Murali).
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like dyspnoea, wheezing, cough, expectoration, disability and sleep disturbances
also significantly reduced in DCBT1234-Lung KR and the biomedical group patients,
but not in the placebo arm.
Conclusions: DCBT1234-Lung KR was equivalent, if not better than the present day
treatment with salbutamol, theophylline and bromhexine combination in COPD
patients and this was ascertained using FEV1 and ABG values.
& 2005 Elsevier Ltd. All rights reserved.Introduction
COPD, which is recognized by both the American
Thoracic Society and the European Respiratory
Society, is a disorder that is characterized by
reduced maximal expiratory flow1 and slow forced
emptying of the lungs1; features that do not change
markedly over several months.2,3 This limitation in
airflow is only minimally reversible with broncho-
dilators. This is a serious respiratory disorder which
primarily occurs on account of smoking.4 The
Global Burden of Diseases studies2 has found that
COPD was the 6th commonest cause of death
worldwide and the prediction is it will move to
the 3rd position. According to World Health
Organization (WHO), this is the 4th largest killer
disease already. COPD is associated with significant
disability and restriction in daily activities.
COPD comprises 2 related diseases, chronic
bronchitis and emphysema, one rarely occurring
without a degree of the other. The pathological
basis of chronic bronchitis is mucus hypersecretion
secondary to hypertrophy of the glandular ele-
ments of the bronchial mucosa. Emphysema is a
condition, where there is permanent destructive
enlargement of the airspaces distal to the terminal
bronchioles without obvious fibrosis.5 Patients with
COPD have features of both conditions, although
one may be more prominent than the other.5
COPD is a major problem in countries like India
mainly affecting the lower strata and the industrial
workers. As of now, most of the concurrent
medications fail to effectively stop the disease
progress and moreover may be accompanied by
systemic side effects when administered as a
maintenance dose. These drugs can contribute to
side effects like tremors, palpitation, seizures and
Cushingod features.6
Two pilot studies carried out earlier by this group
found that the plant-based formulation, DCBT1234-
Lung KR, improved the patients’ quality of life.
They also tolerated the drug very well without any
side effects.7 The 1st pilot study was a double-blind
randomized placebo controlled clinical trial, with
30 patients, 15 in each arm. The objective of the
trial was to observe improvement of clinicalsymptoms on the usage of DCBT1234-Lung KR in
comparison to placebo for a week. The absence of
clinical symptoms like dyspnoea, wheezing, cough,
expectoration, disability and sleep disturbances
were scored as 0 and 1, 2, or 3 corresponding to
mild, moderate and severe. Patients administered
with DCBT1234-Lung KR showed improvement in
the clinical symptoms studied. The 2nd study
was an open trial with 30 patients for a period of
12 weeks with the primary objective of recording
any improvement of 200mL in FEV1 values and/or
attainment of 90% PaO2 in arterial blood gas (ABG)
values. Patients administered with DCBT1234-Lung
KR showed statistically significant improvement
over the placebo group. Both the trials were
approved by the ethics committee of the respective
hospitals and patients signed the consent form.
The present study was designed with a structured
protocol with the primary objective of observing
improvement in pulmonary function and ABG in
patients administered with DCBT1234-Lumg KR in
comparison with a placebo and a biomedical arm
for a period of 24 weeks.Methods
The hospital ethics committee had earlier approved
a 2-week run in period without any medication to
the volunteers of the trial to be inducted into the
study. Volunteers, between 35 and 85 years of age
having COPD with moderate and stable symptoms
for the previous 1 year, maintained on drugs such as
salbutamol, theophylline, bromhexine, predniso-
lone, inhaled corticosteroids such as ipratropium
bromide singly or in combination, without requiring
hospitalization, with a smoking history of 20 pack
years, showing little (o10%) or no improvement in
FEV1 on the baseline recordings (15min after the
administration of 200 mg, 2 puffs of inhaled
salbutamol with a gap of 5min between puffs),
ABG percentage of less than 85% of oxygen
saturation were included in the study conducted
at the Government Hospital for Thoracic Medicine
(GHTM), Chennai, India.
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nasal allergy, chest radiographs to confirm COPD
and to rule out bronchial asthma and other lung
diseases, patients suffering from concurrent sys-
temic diseases, which would include cardiopulmon-
ary and other diseases such as tuberculosis,
pulmonary eosinophilia, cancer, congestive failure,
hepatic dysfunction, neurological disorders and
diarrhoeal disorders were excluded from the trial.
Fully treated pulmonary tuberculosis was not an
exclusion criterion and patients showing less than
10 g% haemoglobin level and exhibiting short
seasonal changes of less than 4 weeks duration
were also excluded from the study.Study design
The 24-week study was a double-blind randomized
placebo controlled clinical trial with 3 arms;
DCBT1234-Lung KR, a biomedical and a placebo
arm. The hospital ethics committee had approved
the protocol. The primary objective was to observe
improvement of 200mL in FEV1 and/or improved
oxygen tension in the blood (PaO2X90%) and with a
secondary objective to observe improvement in
clinical symptoms in patients.Study medication
The biomedical arm contained salbutamol (12mg/
day) plus theophylline (300mg/day) plus bromhex-
ine (24mg/day), DCBT1234-Lung KR with the plant-
based formulation and the placebo containing
lactose filled in identical capsules of uniform color
and shape and packed in uniform strips. The
combination of salbutamol+theophylline+bromhex-
ine is the standard medication prescribed for the
treatment of COPD in this hospital and oral
corticosteroids are given whenever the patient’s
condition deteriorates. Each generic biomedical
drug was filled in capsules with each capsule
containing 4mg equivalent of salbutamol plus
100mg equivalent of theophylline and 8mg equiva-
lent of bromhexine. Lactose was used in placebo
and as a filler to arrive at uniform weight for the
other 2 drugs.
All patients admitted to the trial were de-
wormed, as outpatients, by administering a tablet
albendazole 400mg, before the commencement of
the trial. Only 1 patient from 1 family was enrolled
to the trial. Patients were instructed to avoid the
use of all drugs, by themselves, for any ailment.
They were advised to consult the treating physician
for any symptom or complaint. The physician madea careful record of all the details of the complaints
and dispensed any essential medication.
Patients were advised to visit the hospital daily
during the 1st week. Subsequently, they visited
every month for follow up and collection of
medication. The patients were instructed to take
3 capsules every day, 1 each after breakfast, lunch
and dinner.
Patients were directed to bring at each visit
the drug container supplied during the previous
attendance, along with any unconsumed capsules.
The physician interrogated the patient regarding
the regularity of drug intake and also recorded the
number of unconsumed capsules in the container if
any. A new container with drugs (for the next
month) was issued each month. The investigating
centre provided direct access facility for the
patient all round the clock for any emergency.
Before signing the consent form, information and
details of the trial were given to each patient and
were informed of the option to withdraw from the
study at any time without assigning any reason. The
principal investigator could withdraw any patient
from the trial if the patient showed any deteriora-
tion of vital signs of kidney function or elevated
liver or cardiac enzymes. Monthly review meetings
between the investigators, physicians and the trial
coordinators were conducted to monitor the pro-
gress and compliance of the trial.Study visits
Comprehensive assessment comprising history, clin-
ical assessment, laboratory investigations and lung
function tests were recorded before the medication
dispensation. Clinical assessment was done daily in
the 1st week and at monthly intervals thereafter.
The laboratory investigations were performed on
the 7th day, 3rd month, and at the end of the 6th
month. Lung function tests were recorded twice a
day in the 1st week and then monthly thereafter.
ABG values were recorded every month.Examinations
Clinical assessment included dyspnoea, wheezing,
cough, expectoration, disability and sleep distur-
bances were recorded daily in the 1st week and
subsequently every month. They were assessed
individually as absent, mild, moderate and severe
with scores of 0, 1, 2 and 3. Lung function tests
were recorded twice a day (at 11 a.m. and 5 p.m.)
in the 1st week. Subsequently, it was done every
month at the outpatient department of the
hospital. ABG (PaO2) was analyzed every month.
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lung function machine (P.K. Morgan, UK) and ABG
analysis was carried out in model 1312 Instrumen-
tation Laboratory machine (USA).Statistical and other analyses
Scores of 0, 1, 2 and 3 were used in clinical
symptoms such as dyspnoea, wheezing, cough,
expectoration, disability and sleep disturbances
that were assessed as absent, mild, moderate and
severe, respectively. The mean values of baseline
in comparison to the values on completion of the
study for each of the arms for the above para-
meters were computed and standard deviation
determined. The Mann–Whitney test was per-
formed to find any variations in the baseline and
if found, inter-group comparisons were done using
the Bonferrroni’s test to identify the significantly
different groups. Pulmonary function values are
expressed as mean7standard deviation (SD). The
paired ‘t’ test was used to analyze the improve-
ment of clinical symptoms, FEV1 and PaO2 in the
patients before and after the trial within the group
and analysis of variance (ANOVA) was used to study
variations between the groups. A
’ ’
P’’ value of
o0.05 is considered as statistically significant.Composition of DCBT1234-Lung KR
The composition of the plant-based formulation,
DCBT1234-Lung KR is listed in Table 1.Results
Recruitment of patients took 8 months. Out of 135
patients recruited in this study, 105 patients
completed the 6-month study with 32 patients in
the biomedical arm, 39 patients in DCBT1234-Lung
KR arm and 34 patients in placebo arm. During the
course of the trial, 6 patients in DCBT1234-Lung KR
arm, 13 patients in the biomedical arm and 11
patients in the placebo arm were lost to follow up.Table 1 Composition of DCBT1234-Lung KR.
Botanical names English n
Bryonia alba Bryonia
Cephaelis ipecacuanha Ipecac
Drosera peltata Sun-dew
Lactose and other excipients —Table 2 outlines the medical history and the
baseline demographic data of the patients. All
patients were male. The mean weight, body mass
index (weight in kg/height in m2) and haematolo-
gical parameters for all the 3 arms were similar.
Placebo arm had higher PFT values than the other 2
arms. However, the Mann–Whitney test indicated
that all the 3 arms had similar baseline values
including FEV1. The mean predicted FEV1 values,
FEV1/FVC ratio and the ABG values were also
similar in all the 3 arms. Good compliance
(490%) with the medication dispensed in all the 3
arms were recorded when empty blisters and
unconsumed capsules were counted.
Signs and symptoms
Signs and symptoms of the patients in the study
were analyzed individually and only the baseline
(initial) and 6th month (final) values of each
symptom are represented in Table 3. DCBT1234-
Lung KR group patients exhibited improvement in
all the clinical symptoms studied while the biome-
dical drug did not control dyspnoea and disability.
Pulmonary function tests
The mean baseline FEV1 values of all the 3 arms
were similar (P ¼ 0:39). Mean FEV1 values of the
baseline and the end of the trial showed statisti-
cally significant improvement (Po0:05; 95% sig-
nificance) in DCBT1234-Lung KR arm, but not in the
biomedical and placebo arms (Table 3). Twenty-
four per cent of DCBT1234-Lung KR patients, 19% of
biomedical drug patients and 12% of placebo
patients showed 200mL improvement in FEV1
values at the end of the trial (Table 4). The mean
values of PaO2 presented in Table 3 showed
DCBT1234-Lung KR group exhibited statistically
significant (Pp0:05) improvement at the end of
the trial whereas the biomedical and placebo group
patients failed to demonstrate the improvement. It
was also noticed that except 6 patients in the
DCBT1234-Lung KR arm, none in the other arms
exhibited the desired improvement to more than
90% oxygen saturation in blood (Table 4).ames Quantity of a.i. (per capsule)
75–80 mg of cucurbitacins
100–110 mg of emetine
90–100 mg of plumbagin
q.s.
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Table 2 Demographic and baseline information of the patients.
Characteristic DCBT1234-LungKR
(n ¼ 39)
Salbutamol+theophyline
+bromohexine (n ¼ 32)
Placebo
(n ¼ 34)
Mean age (years) 52 53 53
Range (years) (35–74) (35–81) (38–80)
Mean weight (kg) 48.1876.85 49.5676.93 50.7677.02
Mean BMI 18.877 4.29 19.2474.32 19.5374.35
Mean eosinophil count (cells/cmm) 250.3715.60 260715.87 200714.14
Mean Hb (g%) 10.673.21 10.373.15 10.673.20
Smoking history (in pack years) 21.4674.57 22.4774.66 23.8174.81
Mean FEV1
 (L/s) 1.3270.61 1.2270.60 1.4670.66
Mean FEV1 (predicted) (L/s) 2.8170.61 2.8070.47 2.7870.51
Mean FVCy (L) 2.0670.71 1.9070.64 2.1570.59
Mean FEF (25–75%)z (L/s) 1.1270.82 1.0170.94 1.3671.23
Mean PEFRz (L/min) 280.60795.17 270.307114.67 311.407116.89
FEV1/FVC ratio 0.6370.15 0.6370.15 0.6470.15
7Standard deviation (SD).
FEV1 ¼ forced expiratory volume in 1 s.
yFVC ¼ forced vital capacity.
zFEF ¼ forced expiratory flow.
zPEFR ¼ peak expiratory flow rate.
Table 3 Signs and symptoms, FEV1 and PaO2 of COPD patients.
Signs and symptoms DCBT1234-Lung KR
(n ¼ 39)
Salbutamol+theophylline+
bromhexine (n ¼ 32)
Placebo
(n ¼ 34)
Dyspnoea
Baseline 2.2571.64 0.7570.50 3.0071.73
End of the trial 1.1471.35* 1.0071.41ns 2.6671.15ns
Wheezing
Baseline 1.3372.14 0.2570.50 2.6772.52
End of the trial 0.0070.00* 0.0070.00ns 2.3370.58ns
Cough
Baseline 1.2971.60 1.2571.26 0.5070.70
End of the trial 1.0071.41* 1.0071.41ns 1.0070.90ns
Expectoration
Baseline 1.4371.90 1.2070.84 3.0072.83
End of the trial 0.5770.13* 0.8570.50ns 3.0070.00ns
Disability
Baseline 1.3371.67 1.5071.85 2.2972.21
End of the trial 0.6471.21ns 2.0071.92ns 2.1471.67ns
Disturbances in sleep
Baseline 1.7071.16 0.8070.42 2.0070.89
End of the trial 0.0870.29* 0.2070.42ns 2.3670.42ns
FEV1
Baseline 1.3270.61 1.2270.60 1.4370.66
End of the trial 1.5070.72* 1.0470.36ns 0.7570.15ns
PaO2
Baseline 80.83716.52 82.78728.02 83.93719.57
End of the trial 92.0370.76* 81.8078.39ns 84.0071.02ns
Po0:05; ns—not significant.
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Table 4 Number of patients showing improvement in FEV1 and PaO2.
Drug type No. of
patients
taken for
analysis
Number of patients shown
4200mL improvement in
FEV1 after 6 months
Number of patients shown
improvement of 490%
PaO2 after 6 months
DCBT1234-Lung KR 39 9 23% 6 15%
Salbutamol+theophylline+bromhexine 32 6 15% 0 0%
Placebo 34 4 10% 0 0%
Total 105 19 49% 6 6%
P.M. Murali et al.44Discussion
Several authors have expressed their reservations
in using complementary and alternative medicine
for the treatment of a number of diseases as they
have opined that a randomized clinical trial with a
matching placebo under controlled conditions with-
out any bias is necessary to validate the efficacy of
plant-based formulations.8 In this study, with a
plant-based formulation, DCBT1234-Lung KR, be-
sides a matching placebo, we felt that it would be
incisive to also add a biomedical arm to the study
for comparing the efficacy of the plant-based
formulation.
The demography of the patients in this study was
very similar in nature. All the patients inducted
were males only. The dropouts were higher in the
biomedical arm and placebo arm followed by
DCBT1234-Lung KR. Lowest dropouts in the
DCBT1234-Lung KR arm probably suggesting that
patients felt comfortable with the plant-based
formulation as evinced from the results of the
clinical symptoms. Most of the clinical symptoms
were significantly reduced in DCBT1234-Lung KR
patients.
FEV1 is the most important spirometry test in
diagnosing and monitoring improvement in COPD
patients.9 An increase of 200mL or 15% in the FEV1
values would be rated as a significant improvement
in such patients. Though only 23% of Lung KR
patients showed 200mL improvement in FEV1
values, the biomedical arm showed improvement
only in 19% patients. A similar trend was also seen
in the PaO2 values of both the arms. Except 6
patients in DCBT1234-Lung KR arm, none in any
other arm exhibited improvement in ABG value to
attain 90% oxygen saturation.
The plants used in the formulation have proven
record in their usefulness in the treatment of
respiratory diseases. Bryonia alba has been used in
Homoeopathy as one of the ingredients for treat-
ment of whooping cough and bronchitis.10 Droserahas been used in the treatment of deep hoarse
cough. The genus Drosera contains naphthoqui-
nones considered as the main constituent with anti-
spasmodic, demulcent, and expectorant activities.
Plumbagin of Drosera is active against Streptococ-
cus, Staphylococcus and Pneumococcus species. Its
relaxing effect upon involuntary muscles helps in
the symptomatic relief in respiratory illnesses.11
Mucolytic activity and thinning of sputum by the
same plant has also been recorded.12 Another
ingredient of DCBT1234-Lung KR, ipecac, contains
the alkaloids, emetine and cephaeline, which has
been used as an emetic, diaphoretic and expector-
ant since the 18th century.13
It is interesting to note that DCBT1234-Lung KR a
multicomponent plant-based formulation is effec-
tive in the management of COPD without side
effects associated with modern biomedical drugs.
The investigator and his group are currently working
on understanding the mechanism of action of the
multicomponent formulation DCBT1234-Lung KR.Acknowledgements
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